Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
Phase 4
730
about 3.6 years
6+
59 sites in AL, AZ, CA +29
About this study
This trial is testing whether a single aminoglycoside antibiotic, combined with a beta-lactam antibiotic, is as effective as two different antibiotics (tobramycin and a beta-lactam) in treating pulmonary exacerbations in people with cystic fibrosis. The goal is to determine if using one type of antibiotic provides the same improvement in lung function and symptoms compared to using two types.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Aminoglycoside
- 2.Take Beta-lactam antibiotic
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
antibiotic
Primary: Absolute Change in FEV1 % Predicted at Week 4 in Aminoglycoside (AG) Study, Incidence of Adverse Events (AEs) in Aminoglycoside (AG) Study Intervention Arms
Respiratory